The Motley Fool Previous Page


Novartis' Life-Changing Blockbuster Drug

http://www.fool.com/investing/general/2013/03/18/novartis-life-changing-blockbuster-drug.aspx

Max Macaluso, Ph.D.
March 18, 2013

For many years, chronic myeloid leukemia, or CML, was a diagnosis that both doctors and patients could do little about. The commonly prescribed course of treatment involved interferon, a drug that has terrible side effects and proved to be ineffective for this indication. However, the revolutionary discovery of the BCR-Abl gene and Novartis' (NYSE: NVS) Gleevec completely changed the way CML is treated today. 

In the following video, Dr. Margaret I. Cuomo, author of the book A World Without Cancer, and Motley Fool analyst Max Macaluso discuss Gleevec's success and why other types of cancers have been more difficult to treat. A transcript is provided below the video.

Much like Novartis, Celgene is also developing more effective drugs for the treatment of cancer